Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2025 | Advancements in stage II-III NSCLC management: neoadjuvant chemo-IO and postoperative strategies

Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, discusses key developments in the management of stage 2 and stage 3 non-small cell lung cancer (NSCLC), particularly the role of neoadjuvant and perioperative chemoimmunotherapy. He highlights ongoing debates on defining operability, optimal post-treatment strategies for patients who progress after neoadjuvant therapy, and the evolving role of postoperative radiotherapy in light of improved techniques. This interview took place at the BTOG 2025 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.